4D Molecular Therapeutics (NASDAQ:FDMT) executives said the company is seeing strong clinical trial momentum for its lead ...

Key market opportunities for Lucentis include its broad approval for multiple retinal diseases, its proven clinical efficacy, and strong physician trust. Despite competition, its established global ...

A new study published in the Journal of the American Medical Association found that administration of anti–vascular ...

LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – – Continued favorable safety profile observed in masked ...

The urgency is clear. Africa records roughly 1.2 million new cancer cases annually and more than 700,000 cancer-related deaths, with incidence expected to rise sharply. Diabetes and its complications ...

Imran and Bushra Bibi remain incarcerated in Rawalpindi's Adiala Jail. They were sentenced on December 20, 2025, to 17 years ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received ...

Gene therapy for neovascular age-related macular degeneration is linked to positive anatomical changes, but variable visual outcomes.

Trial misses goal: Tonabersat did not significantly reduce central retinal thickness versus placebo after six months in the overall study population. Signals in subgroups: Analyses indicated greater ...

Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease May 8, 2026 12:30 PM ...

On track to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026Well-capitalized with $106.9 million in ...

ALLUVIUM showed vamikibart Q8W/Q4W improved DME outcomes but underperformed ranibizumab for BCVA (+4.6 to +7.1 vs +13 letters ...